Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer

Olaparib is recently approved as an anti-tumor agent for several cancers, including castration-resistant prostate cancer, which inhibits poly (adenosine diphosphate-ribose) polymerase, a DNA repair factor. Since olaparib is a newly approved drug, there are few reports of skin disorders that may be t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekine, Mana, Terui, Hitoshi, Fujimura, Taku, Asano, Yoshihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294207/
https://www.ncbi.nlm.nih.gov/pubmed/37384205
http://dx.doi.org/10.1159/000530981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294207/
https://www.ncbi.nlm.nih.gov/pubmed/37384205
http://dx.doi.org/10.1159/000530981

Ejemplares similares